Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00579163 | Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | active not recruiting | — | 992 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04204811 | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | active not recruiting | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 |
| clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321730 | Surgeons' Ability to Predict Pathological and Molecular Features of Peritoneal Carcinomatosis in Ovarian Cancer(Visual-PC) | not yet recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jan 7, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer(FIRST) | active not recruiting | Phase 3 | 1,400 | Tesaro, Inc.INDUSTRY | 19 | Dec 31, 2025 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT05220033 | Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer | active not recruiting | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT04670068 | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | active not recruiting | Phase 1 | 4 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06971744 | Autophagy Maintenance (AUTOMAIN) | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06017557 | Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer(PREDAtOOR) | recruiting | N/A | 151 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06963268 | Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)(SENTOV II) | recruiting | Phase 3 | 200 | Instituto de Investigacion Sanitaria La FeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07261683 | Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07295132 | RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) | not yet recruiting | Phase 2 | 160 | Asan Medical CenterOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07030907 | A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06855069 | HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 468 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07285941 | Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06611072 | OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study(RENAISSANCE) | recruiting | N/A | 90 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.(SOLO-1) | active not recruiting | Phase 3 | 450 | AstraZenecaINDUSTRY | 15 | Dec 10, 2025 | clinicaltrials |
| NCT07271914 | PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors(PONDER) | not yet recruiting | N/A | 390 | Ospedale Santa Croce-Carle CuneoOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07273396 | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 53 | Seoul National University HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07269574 | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance | not yet recruiting | — | 600 | Tongji HospitalOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07267780 | Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. | not yet recruiting | — | 130 | National Cancer Institute, NaplesOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07268469 | Minimal Residual Disease in Solid Malignancies(IMRD) | not yet recruiting | N/A | 840 | European Institute of OncologyOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT04284969 | PROADAPT-ovary/EWOC-2 | recruiting | N/A | 292 | Hospices Civils de LyonOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07057167 | Prediction of Ovarian Cancer Histotypes and Surgical Outcome(PANtHer-AI) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT07239622 | Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma | not yet recruiting | Phase 2 | 36 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT05236686 | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer | recruiting | N/A | 94 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03954171 | Platino-resistance in Ovarian Cancer(PlatinOv) | recruiting | N/A | 600 | Institut Claudius RegaudOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05773859 | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer(NEODOC) | recruiting | Phase 1 / Phase 2 | 10 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05984875 | The Immune Landscape of Epithelial Ovarian Cancer(IOSI-GYNE-001) | recruiting | — | 74 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06588322 | Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy(ATROVA) | recruiting | N/A | 130 | Institut Claudius RegaudOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04473833 | Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer | recruiting | N/A | 65,000 | John R van NagellOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT01223248 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | active not recruiting | Phase 3 | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Nov 4, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02346747 | A Trial of Vigil for Participants With Ovarian Cancer(VITAL) | active not recruiting | Phase 2 | 92 | Gradalis, Inc.INDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 7, 2026source: clinicaltrials